Last reviewed · How we verify

GP+CCRT — Competitive Intelligence Brief

GP+CCRT (GP+CCRT) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy with concurrent chemoradiotherapy. Area: Oncology.

phase 3 Combination chemotherapy with concurrent chemoradiotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

GP+CCRT (GP+CCRT) — Guiyang Medical University. GP+CCRT is a combination treatment regimen pairing gemcitabine/cisplatin chemotherapy with concurrent chemoradiotherapy to enhance tumor control through synergistic cytotoxic and radiation effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GP+CCRT TARGET GP+CCRT Guiyang Medical University phase 3 Combination chemotherapy with concurrent chemoradiotherapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy with concurrent chemoradiotherapy class)

  1. Guiyang Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GP+CCRT — Competitive Intelligence Brief. https://druglandscape.com/ci/gp-ccrt. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: